Condition: Behavioral Activation · Major Depressive Disorder · Anxiety Disorders · Sponsor: University of Manitoba
The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.
This description comes directly from the study's public registry record.
Abdullah A Maruf, BPharm, MPharm, PhD · 204-318-2575 · abdullah.maruf@umanitoba.ca
Always discuss trial participation with your own doctor first.
| Shared Health Facilities | Winnipeg, Manitoba, Canada | Recruiting |
| University of Manitoba College of Pharmacy | Winnipeg, Manitoba, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06763081